These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2423420)

  • 1. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Haemostasis; 1986; 16(2):106-15. PubMed ID: 2423420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
    Fuchs HE; Trapp HG; Griffith MJ; Roberts HR; Pizzo SV
    J Clin Invest; 1984 Jun; 73(6):1696-703. PubMed ID: 6202716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 6. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration.
    Dawes J; Bara L; Billaud E; Samama M
    Haemostasis; 1986; 16(2):116-22. PubMed ID: 3710290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of low-molecular heparin on blood coagulation].
    Harenberg J; de Vries JX; Weber E; Zimmermann R
    Dtsch Med Wochenschr; 1984 Jun; 109(24):951-4. PubMed ID: 6734448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions.
    Brace LD; Fareed J
    Thromb Res; 1986 Jun; 42(6):769-82. PubMed ID: 3726798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in man.
    Fareed J; Walenga JM; Hoppensteadt DA; Emanuele RM
    Haemostasis; 1986; 16(2):123-38. PubMed ID: 2423421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
    Holmer E; Kurachi K; Söderström G
    Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.
    Bratt G; Törnebohm E; Lockner D; Bergström K
    Thromb Haemost; 1985 Apr; 53(2):208-11. PubMed ID: 4024029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa.
    Elödi S; Váradi K
    Thromb Res; 1978 May; 12(5):797-807. PubMed ID: 675589
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical and pharmacological studies on the interaction of PK 10169 and its subfractions with human platelets.
    Brace LD; Fareed J; Tomeo J; Issleib S
    Haemostasis; 1986; 16(2):93-105. PubMed ID: 3710299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
    Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
    Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of low molecular weight heparin (FR-860) on coagulative and fibrinolytic activities].
    Hamano S; Kinukawa M; Komatsu H; Ikeda S; Sakuragawa N
    Nihon Yakurigaku Zasshi; 1989 Oct; 94(4):243-9. PubMed ID: 2613105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.
    Stern DM; Nawroth PP; Kisiel W; Handley D; Drillings M; Bartos J
    J Clin Invest; 1984 Dec; 74(6):1910-21. PubMed ID: 6439737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.